SRR6013599
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.470
- WNT_BETA_CATENIN_SIGNALING+0.440
- HEDGEHOG_SIGNALING+0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.380
- NOTCH_SIGNALING+0.360
- INTERFERON_GAMMA_RESPONSE+0.350
- MYOGENESIS+0.340
- UV_RESPONSE_DN+0.300
- TGF_BETA_SIGNALING+0.230
- APICAL_JUNCTION+0.210
Top 10 suppressed
- MYC_TARGETS_V1-0.630
- MYC_TARGETS_V2-0.620
- E2F_TARGETS-0.590
- MTORC1_SIGNALING-0.570
- G2M_CHECKPOINT-0.520
- OXIDATIVE_PHOSPHORYLATION-0.510
- CHOLESTEROL_HOMEOSTASIS-0.470
- FATTY_ACID_METABOLISM-0.440
- PROTEIN_SECRETION-0.440
- GLYCOLYSIS-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-5444-01A-02R-1514-07 | — | — | 0.899 |
| 2 | SRR15030864 | — | — | 0.897 |
| 3 | GSM5359411 | — | — | 0.897 |
| 4 | TCGA-QK-A8Z9-01B-11R-A39I-07 | — | — | 0.885 |
| 5 | TCGA-55-A48Z-01A-12R-A24X-07 | — | cohortA1 | 0.880 |
| 6 | SRR12202445 | — | — | 0.877 |
| 7 | ULC0428T_S51 | — | cohortA1 | 0.877 |
| 8 | 44eb0b78-9761-4131-b831-85e765a24e6b | — | — | 0.875 |
| 9 | X0e8b5ba7.3bee.4627.a8b6.f94263f78e3e | — | cohortMD2 | 0.873 |
| 10 | TCGA-K4-A3WS-01A-11R-A22U-07 | — | — | 0.872 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.440 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.420 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.380 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.360 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.350 | Idelalisib | — uncovered |
| MYOGENESIS | 0.340 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.230 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.210 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.160 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.150 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.120 | Idelalisib | — uncovered |
| COMPLEMENT | 0.090 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.090 | Idelalisib | — uncovered |
| COAGULATION | 0.080 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.080 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.060 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.020 | Remibrutinib | — uncovered |